In good health, Megan Pfeffer, BHSc, CPN Clinical Nutritionist | Founder, I Choose Health Board Member, Lipedema World Alliance Advisory Board Member, Lipoedema Australia References Aneke-Nash, C., Hung, K
The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects
Keywords: GLP-1 receptor agonists, Anesthesia, Perioperative period, Fasting, Ultrasound Background Nowadays, metabolic disorders are increasing rapidly worldwide, and incretin-based therapies have gained a pivotal role in the management of type 2 diabetes and obesity [1, 2]
Medicare Part D coverage for GLP-1 weight loss medications is currently excluded, but CMS is exploring pilot programs that could begin as early as 2027
Abstract Background Bariatric surgery (BS) is the most effective treatment for severe obesity, but a significant proportion of patients experience insufficient weight loss (IWL) or weight regain
